Dae Gon Ha
Stock Analyst at Stifel
(2.67)
# 2,084
Out of 4,944 analysts
46
Total ratings
36.84%
Success rate
8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reinstates: Buy | $89 | $65.14 | +36.63% | 4 | Aug 11, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $6.56 | +204.88% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $3.08 | -2.60% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $81.14 | -8.80% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $6.84 | -56.14% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $11.00 | +481.82% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $149.36 | +47.30% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $28.97 | +338.38% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.09 | +1,453.40% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.81 | +372.44% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.93 | +652.69% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $97.95 | -74.48% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $7.19 | +122.53% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $10.06 | +2,733.00% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.02 | +890.10% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.58 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $26.58 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.53 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.82 | +1,370.59% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $9.94 | +4,828.93% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Aug 11, 2025
Reinstates: Buy
Price Target: $89
Current: $65.14
Upside: +36.63%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $6.56
Upside: +204.88%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $3.08
Upside: -2.60%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $81.14
Upside: -8.80%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $6.84
Upside: -56.14%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $11.00
Upside: +481.82%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $149.36
Upside: +47.30%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $28.97
Upside: +338.38%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.09
Upside: +1,453.40%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.81
Upside: +372.44%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.93
Upside: +652.69%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $97.95
Upside: -74.48%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $7.19
Upside: +122.53%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $10.06
Upside: +2,733.00%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.02
Upside: +890.10%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.58
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $26.58
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $8.53
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.82
Upside: +1,370.59%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $9.94
Upside: +4,828.93%